ESPERION THERAPEUTICS INCESPERION THERAPEUTICS INCESPERION THERAPEUTICS INC

ESPERION THERAPEUTICS INC

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪353.47 M‬EUR
−0.90EUR
‪−189.58 M‬EUR
‪105.40 M‬EUR
‪154.70 M‬
Beta (1Y)
4.43

About Esperion Therapeutics, Inc.

CEO
Sheldon L. Koenig
Headquarters
Ann Arbor
Employees (FY)
240
Founded
1998
FIGI
BBG007HLD3L5
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 0ET is 1.99 EUR — it has decreased by 8.72% in the past 24 hours. Watch ESPERION THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ESPERION THERAPEUTICS INC stocks are traded under the ticker 0ET.
0ET stock has fallen by 6.67% compared to the previous week, the month change is a 4.33% rise, over the last year ESPERION THERAPEUTICS INC has showed a 57.28% increase.
We've gathered analysts' opinions on ESPERION THERAPEUTICS INC future price: according to them, 0ET price has a max estimate of 14.95 EUR and a min estimate of 2.34 EUR. Watch 0ET chart and read a more detailed ESPERION THERAPEUTICS INC stock forecast: see what analysts think of ESPERION THERAPEUTICS INC and suggest that you do with its stocks.
0ET reached its all-time high on Mar 19, 2015 with the price of 113.99 EUR, and its all-time low was 0.68 EUR and was reached on Oct 26, 2023. View more price dynamics on 0ET chart.
See other stocks reaching their highest and lowest prices.
0ET stock is 45.64% volatile and has beta coefficient of 4.43. Track ESPERION THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is ESPERION THERAPEUTICS INC there?
Today ESPERION THERAPEUTICS INC has the market capitalization of ‪353.47 M‬, it has decreased by 19.79% over the last week.
Yes, you can track ESPERION THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
ESPERION THERAPEUTICS INC is going to release the next earnings report on Jul 30, 2024. Keep track of upcoming events with our Earnings Calendar.
0ET earnings for the last quarter are 0.32 EUR per share, whereas the estimation was 0.05 EUR resulting in a 598.27% surprise. The estimated earnings for the next quarter are −0.17 EUR per share. See more details about ESPERION THERAPEUTICS INC earnings.
ESPERION THERAPEUTICS INC revenue for the last quarter amounts to ‪127.65 M‬ EUR, despite the estimated figure of ‪77.79 M‬ EUR. In the next quarter, revenue is expected to reach ‪43.66 M‬ EUR.
0ET net income for the last quarter is ‪56.55 M‬ EUR, while the quarter before that showed ‪−51.05 M‬ EUR of net income which accounts for 210.79% change. Track more ESPERION THERAPEUTICS INC financial stats to get the full picture.
No, 0ET doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 29, 2024, the company has 240.00 employees. See our rating of the largest employees — is ESPERION THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ESPERION THERAPEUTICS INC EBITDA is ‪−19.93 M‬ EUR, and current EBITDA margin is −133.58%. See more stats in ESPERION THERAPEUTICS INC financial statements.
Like other stocks, 0ET shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ESPERION THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ESPERION THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ESPERION THERAPEUTICS INC stock shows the sell signal. See more of ESPERION THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.